Overview
Anthralin (1,8‐dihydroxy‐9anthrone, dithranol) is an older anti-psoriatic agent that was first synthesized as a derivative of chrysarobin, obtained from the araroba tree in Brazil over 100 years ago. Adverse effects of anthralin include irritation and discoloration of the skin . This specific property of the molecule inspired workers to study details of its pharmacology. It is important to consider that the drug is relatively innocuous, yet effective, and systemic side effects have not been observed with this anthralin, in contrast to a wide variety of systemic and topical therapies for psoriasis . Anthralin is also known as dithranol. It is a main active ingredient in topical skin formulations for the treatment of psoriasis. Various formulations of the drug are available, including solutions, foams, and shampoos . The chemical structure of anthralin allows for dual solubility, permitting the compound to be absorbed well through the epidermis . Anthralin has also been studied in the treatment of warts, showing promising results . Salicylic acid is frequently added to anthralin to augment the stability of anthralin and to increase its penetration and efficacy .
Indication
Stable plaque psoriasis of the skin and scalp . It is also used topically in the management of psoriasis, dermatoses, and alopecia areata. Anthralin is also used in biomedical research due to its effect on EGFR autophosphorylation .
Associated Conditions
- Psoriasis Chronic
- Quiescent Psoriasis
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2017/11/21 | Phase 4 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Elorac Inc. | 42783-111 | TOPICAL | 1 g in 100 g | 10/17/2014 | |
| Elorac Inc. | 42783-101 | TOPICAL | .012 g in 1 g | 1/29/2010 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| WCL, Psorin Ointment Psorin | 33696 | Cortecs (OM) Pty Limited | Medicine | A | 12/3/1991 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| ANTHRAFORTE 1 OINTMENT 1% | medican technologies inc. | 00566756 | Ointment - Topical | 1 % | 12/31/1984 |
| ANTHRANOL CREAM 0.2% | medican technologies inc. | 00537608 | Cream - Topical | 0.2 % | 12/31/1982 |
| ANTHRANOL CREAM 0.4% | medican technologies inc. | 00537616 | Cream - Topical | 0.4 % | 12/31/1982 |
| ANTHRANOL CREAM 0.1% | medican technologies inc. | 00537594 | Cream - Topical | 0.1 % | 12/31/1982 |
| ANTHRASCALP LOTION 0.4% | medican technologies inc. | 00695351 | Lotion - Topical | 0.4 % | 12/31/1987 |
| ANTHRAFORTE 2 OINTMENT 2% | medican technologies inc. | 00566748 | Ointment - Topical | 2 % | 12/31/1984 |
| MICANOL CREAM | canderm g.p. | 02233053 | Cream - Topical | 1 % | 5/6/1998 |
| MICANOL 3% CREAM | canderm g.p. | 02238160 | Cream - Topical | 3 % | 9/1/1998 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.